Public health authorities insist they are guided by science. But when it comes to nicotine, policy is driven less by toxicology than by symbolism. Regulators approve long-term daily nicotine use through patches, gum and lozenges, while portraying nicotine as inherently dangerous when delivered through consumer products like vapes or pouches. This contradiction is neither subtle nor tenable.
The belief that nicotine causes most smoking-related diseases is widespread—and wrong. Nicotine’s effects are what keeps people smoking, and its use may lead to dependency. But it is not the direct cause of smoking-related cancer, emphysema or cardiovascular disease. What kills people who smoke is the tar, carbon monoxide, fine particulates and thousands of toxic by-products created by burning tobacco.
This distinction is well established in science, even if it is often obscured in public messaging. The US Food and Drug Administration has acknowledged that nicotine is not the main cause of smoking-related illness. The Centers for Disease Control and Prevention similarly notes that nicotine is not a carcinogen. The World Health Organization’s cancer research arm, the International Agency for Research on Cancer, does not classify nicotine as cancer-causing.
The clearest evidence that regulators do not believe nicotine is inherently unsafe is their attitude to nicotine replacement therapy. Patches, gums, lozenges, sprays and inhalers have been available and medically approved for decades around the world.
If nicotine were dangerous at these levels, regulators would not allow over-the-counter NRT sales. But they’ve already made a judgment: Nicotine can be used safely long-term.
They are sold over the counter, recommended by doctors, and often used daily for months or years. Many people who smoke are advised to combine products, such as wearing a 21-milligram patch while also using multiple 4-milligram lozenges per day. Total daily nicotine exposure from approved products routinely reaches 20 to 40 milligrams.
If nicotine itself were dangerous at these levels, regulators would not allow NRT sales, certainly not over-the-counter. But regulators have already made a clear judgment: Nicotine can be used safely, long-term, when delivered without combustion. This is not a loophole. It is a regulatory admission.
Yet when nicotine is delivered through consumer products rather than medical ones, the tone changes dramatically. The molecule is identical. Doses are often comparable. Toxicant exposure is dramatically lower than smoking. Still, vaping and nicotine pouches are treated as suspect or dangerous, while cigarettes remain widely available.
This distinction cannot be explained by chemistry or toxicology. Sure, with vaping, trace amounts of other substances are also involved; the dose makes the poison—or in this case, doesn’t. But objections to consumer products widely focus on nicotine itself.
Witness the FDA’s bizarre warnings of the dangers of what it calls “nicotine addiction”—a term that according to modern definitions entails serious harms, not mere dependency. Or the WHO’s claim, among others, that exposure to nicotine harms the developing brain—a phenomenon not illustrated by generations who smoked from a young age.
In reality, it reflects regulators’ discomfort with consumer choice. Medical nicotine is controlled, clinical and gatekept.
Allied organizations and researchers pile on. The American Cancer Society, for instance, obfuscates on the question of whether nicotine is carcinogenic, amid a slew of other warnings about it. And a group of European cardiologists recently issued claims that nicotine is a “potent cardiovascular toxin” in calling for restrictions on consumer products.
NRT is rarely targeted by this outcry. And when regulators know that NRT is safe, their distinction between NRT and vapes or pouches reflects, in reality, their discomfort with consumer choice.
Medical nicotine is controlled, clinical and gatekept. Consumer nicotine disrupts an abstinence-oriented framework that has dominated tobacco control for decades. It also challenges narratives that treat nicotine use as a moral failing rather than a choice on a spectrum of risk.
One common objection to vaping and other consumer nicotine products is that they deliver nicotine more rapidly than patches or gum, producing sharper “spikes” in blood nicotine levels. These spikes are often portrayed as dangerous. This misunderstands what matters for health.
Cigarettes are uniquely efficient nicotine delivery devices. Smoke inhalation sends nicotine to the brain within seconds, producing sharp arterial spikes repeated many times per day. These spikes matter for cigarette addiction, but they are not what causes disease.
Trying to hold both positions at once is not precaution. It is incoherence.
Nicotine replacement therapies were deliberately designed to avoid rapid spikes, making them less reinforcing—and less appealing to many people who want to quit smoking.
Vapes sit between these extremes. Modern devices deliver nicotine faster than patches or gum, but generally slower and at lower peaks than cigarettes. Nicotine pouches deliver nicotine even more gradually.
But any concern about spikes is really about dependency and subjective effect, not toxicity. That distinction matters. Cancer and mortality are public health threats. Dependency in the absence of serious harms is a mere regulatory issue.
By refusing to distinguish between nicotine and smoking, regulators produce predictable harms. Cigarettes remain the most accessible nicotine product. Safer alternatives face bans, flavor restrictions and regulatory limbo. Illicit markets grow. People receive misleading health information. Public trust erodes.
Nicotine replacement therapy quietly acknowledges what public messaging denies: Nicotine can be used safely long-term. Science settled this years ago. Policy has not.
Either nicotine is too dangerous to allow patches and gum, or it is safe enough to allow adults to choose lower-risk consumer alternatives to smoking. Trying to hold both positions at once is not precaution. It is incoherence.
Photograph via Wikimedia Commons/Creative Commons 3.0
